Amneal to report fourth quarter and full year 2022 results on march 2, 2023

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) announced today that the company will release its fourth quarter and full year 2022 financial results on thursday march 2, 2023, prior to market open. the company will host a conference call and live webcast with the investment community at 8:30 a.m. eastern time on march 2, 2023. the financial results and live webcast will be accessible through the investor relations section of the company's website at https://investors.amneal.com. to access the call through a conference line, dial 1 (844) 200-6205 (in the u.s.) or 1 (929) 526-1599 (international callers). the access code for the call is 477511. a replay of the conference call will be posted shortly after the call and will be available for seven days. to access the replay, dial 1 (866) 813-9403 (in the u.s.) or +44 (204) 525-0658 (international callers). the access code for the replay is 942331. about amneal amneal pharmaceuticals, inc. (nyse: amrx), headquartered in bridgewater, nj, is a fully integrated essential medicines company. we make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the united states. the company has a diverse portfolio of over 250 products in its generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. in its specialty segment, amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. through its avkare segment, the company is a distributor of pharmaceuticals and other products for the u.s. federal government, retail, and institutional markets. for more, please visit www.amneal.com.
AMRX Ratings Summary
AMRX Quant Ranking